Updated data from the CHRYSALIS-2 study reveals that Johnson & Johnson’s RYBREVANT® plus LAZCLUZE® combination achieves a historic median overall survival of 41.0 months as a first-line therapy for atypical EGFR-mutated advanced non-small cell lung cancer.
Johnson & Johnson has announced groundbreaking Phase 3 results for Tecvayli Multiple Myeloma Treatment, demonstrating its superiority over standard-of-care therapies in improving overall survival as early as the first relapse.
Landmark seven-year results from Pfizer’s CROWN study show LORBRENA (lorlatinib) reduces the risk of disease progression or death by 81% in ALK+ NSCLC, setting a new standard for oncology care.
AstraZeneca has announced a three-month extension to the FDA’s review period for camizestrant, a promising treatment for HR+/HER2- advanced breast cancer with ESR1 mutations.
New results from the POSEIDON study presented at the 94th EAS Congress highlight that cardiovascular inflammation risk persists in 40% of high-risk patients, signaling an urgent need for targeted therapies.
Eli Lilly’s Retatrutide has demonstrated record-breaking efficacy in Phase 2 trials, showing that triple-hormone receptor agonists may be the future of chronic weight management.
Merck has announced that the Phase 3 Trofuse-005 trial evaluating Sacituzumab Tirumotecan (Sac-TMT) successfully met its primary endpoints, offering a new hope for patients with advanced or metastatic NSCLC.
Pfizer has initiated a pivotal Phase 3 study for its 25-valent pediatric pneumococcal vaccine (25vPnC) after Phase 2 data showed a 15-fold increase in immune response against serotype 3.
Semaglutide for MASH (Metabolic Dysfunction-associated Steatohepatitis) is poised to change the landscape of hepatology as Novo Nordisk prepares to unveil highly anticipated data at the [Read More…]
Novartis has announced groundbreaking results from the Phase III PSMAddition trial, revealing that Pluvicto significantly reduces the risk of PSA progression by 58% in patients with metastatic hormone-sensitive prostate cancer.
